Middle East & Africa Clinical Trials Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The clinical trials market in the Middle East and Africa is projected to grow significantly, reaching approximately USD 1,803.78 million by 2031, up from USD 1,234.57 million in 2023, reflecting a compound annual growth rate (CAGR) of 4.9% during the forecast period.

Executive Summary and Market Analysis

The market is divided into key regions: Saudi Arabia, the UAE, South Africa, and the broader Middle East and Africa. The growth in this sector is primarily driven by the increasing incidence of cancer and substantial investments in healthcare infrastructure. Additionally, rising awareness about the benefits of clinical trials and government initiatives to enhance healthcare spending are expected to further stimulate market expansion in the coming years.

Market Segmentation Analysis

The clinical trials market is categorized based on study design, indications, and phase type.

Study Design: The market is split into interventional trials and expanded access trials, with interventional trials dominating the market share in 2023.
Indications: The market is segmented into various therapeutic areas, including autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular diseases, and others. Oncology emerged as the leading segment in 2023.
Phase Type: The market is further divided into phase I, phase II, and phase III trials, with phase II trials holding the largest market share in 2023.

Market Outlook

Clinical trials are essential for assessing the safety and efficacy of new medical products, including drugs, diets, and medical devices, and are integral to the drug development process. According to the National Library of Medicine, around 52,000 new studies were registered in 2020, increasing to approximately 58,000 by 2023. This rise in clinical trials is largely due to the growing prevalence of chronic diseases, which necessitates the development of more effective treatments.

The complexity of clinical trials underscores the importance of meticulous execution and oversight, leading many organizations to outsource these trials to Clinical Research Organizations (CROs). CROs play a crucial role in facilitating clinical trials by providing high-quality services and expertise, thus becoming a vital component of the clinical trial ecosystem. A report by Thermo Fisher Scientific noted that in 2022, CROs managed about 75% of clinical trials, enhancing the efficiency and quality of data for drug developers. This trend of outsourcing is a significant factor driving the growth of the clinical trials market.

Country Insights

The clinical trials market in the Middle East and Africa includes key countries such as Saudi Arabia, South Africa, the UAE, and others. South Africa held the largest market share in 2023. Despite its economic advancements, South Africa faces numerous public health challenges, particularly with tuberculosis (TB) and HIV. The World Health Organization reported that South Africa ranks among the top countries for TB burden, contributing significantly to global TB cases.

To address the rising HIV cases, numerous clinical trials are being conducted in South Africa. Notably, research on drug-resistant TB has led to significant advancements in treatment protocols, as highlighted in a 2022 article discussing trials that resulted in global policy changes. These studies, conducted by the University of the Witwatersrand and the Clinical HIV Research Unit, have shortened treatment durations and improved patient outcomes.

Company Profiles

Key players in the clinical trials market include QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx Research Private Limited, Caidya, Oracle Corp, Medpace Holdings Inc, and SIRO Clinpharm Pvt Ltd. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to their clients.

Product Code: BMIRE00029011

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Middle East & Africa Clinical Trials Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials
- 4.1.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities
4.2 Market Restraints
- 4.2.1 Expensive and Time-Consuming Process
4.3 Market Opportunities
- 4.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
4.4 Future Trends
- 4.4.1 AI-Driven Clinical Trials
4.5 Impact of Drivers and Restraints:

5. Clinical Trials Market - Middle East & Africa Analysis

5.1 Middle East & Africa Clinical Trials Market Revenue (US$ Million), 2021-2031
5.2 Middle East & Africa Clinical Trials Market Forecast Analysis

6. Middle East & Africa Clinical Trials Market Analysis - by Study Design

6.1 Interventional Trials
- 6.1.1 Overview
- 6.1.2 Interventional Trials: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Expanded Access Trials
- 6.2.1 Overview
- 6.2.2 Expanded Access Trials: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Middle East & Africa Clinical Trials Market Analysis - by Indications

7.1 Autoimmune/Inflammation
- 7.1.1 Overview
- 7.1.2 Autoimmune/Inflammation: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Pain Management
- 7.2.1 Overview
- 7.2.2 Pain Management: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Neurological Disorders
- 7.4.1 Overview
- 7.4.2 Neurological Disorders: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Diabetes
- 7.5.1 Overview
- 7.5.2 Diabetes: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Obesity
- 7.6.1 Overview
- 7.6.2 Obesity: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Metabolic Disorders
- 7.7.1 Overview
- 7.7.2 Metabolic Disorders: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Cardiovascular
- 7.8.1 Overview
- 7.8.2 Cardiovascular: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.9 Others
- 7.9.1 Overview
- 7.9.2 Others: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Middle East & Africa Clinical Trials Market Analysis - by Phase Type

8.1 Phase I
- 8.1.1 Overview
- 8.1.2 Phase I: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Phase II
- 8.2.1 Overview
- 8.2.2 Phase II: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Phase III
- 8.3.1 Overview
- 8.3.2 Phase III: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Middle East & Africa Clinical Trials Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East and Africa Clinical Trials Market Overview
- 9.1.2 Middle East & Africa Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Middle East & Africa Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 Saudi Arabia: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.2.1 Saudi Arabia: Middle East & Africa Clinical Trials Market Share - by Study Design
    - 9.1.2.2.2 Saudi Arabia: Middle East & Africa Clinical Trials Market Share - by Indications
    - 9.1.2.2.3 Saudi Arabia: Middle East & Africa Clinical Trials Market Share - by Phase Type
  - 9.1.2.3 South Africa: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.3.1 South Africa: Middle East & Africa Clinical Trials Market Share - by Study Design
    - 9.1.2.3.2 South Africa: Middle East & Africa Clinical Trials Market Share - by Indications
    - 9.1.2.3.3 South Africa: Middle East & Africa Clinical Trials Market Share - by Phase Type
  - 9.1.2.4 United Arab Emirates: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.4.1 United Arab Emirates: Middle East & Africa Clinical Trials Market Share - by Study Design
    - 9.1.2.4.2 United Arab Emirates: Middle East & Africa Clinical Trials Market Share - by Indications
    - 9.1.2.4.3 United Arab Emirates: Middle East & Africa Clinical Trials Market Share - by Phase Type
  - 9.1.2.5 Rest of Middle East & Africa: Middle East & Africa Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.5.1 Rest of Middle East & Africa: Middle East & Africa Clinical Trials Market Share - by Study Design
    - 9.1.2.5.2 Rest of Middle East & Africa: Middle East & Africa Clinical Trials Market Share - by Indications
    - 9.1.2.5.3 Rest of Middle East & Africa: Middle East & Africa Clinical Trials Market Share - by Phase Type

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players
10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Clinical Trials Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 QVIA Holdings Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Parexel International Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 IXICO Plc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Charles River Laboratories International Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 ICON Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 WuXi AppTec Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 SGS SA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Syneos Health Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SIRO Clinpharm Pvt Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Thermo Fisher Scientific Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Laboratory Corp of America Holdings
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
12.12 CliniRx Research Private Limited
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 Financial Overview
- 12.12.5 SWOT Analysis
- 12.12.6 Key Developments
12.13 Caidya
- 12.13.1 Key Facts
- 12.13.2 Business Description
- 12.13.3 Products and Services
- 12.13.4 Financial Overview
- 12.13.5 SWOT Analysis
- 12.13.6 Key Developments
12.14 Oracle Corp
- 12.14.1 Key Facts
- 12.14.2 Business Description
- 12.14.3 Products and Services
- 12.14.4 Financial Overview
- 12.14.5 SWOT Analysis
- 12.14.6 Key Developments
12.15 Medpace Holdings Inc
- 12.15.1 Key Facts
- 12.15.2 Business Description
- 12.15.3 Products and Services
- 12.15.4 Financial Overview
- 12.15.5 SWOT Analysis
- 12.15.6 Key Developments

13. Appendix

13.1 About Us
13.2 List of Abbreviations